![]() ![]() Abbott Laboratories, in August 2020, inked an agreement with the US government for 150 Mn home-based BinaxNOW Covid-19 tests.Sofia 2 Flu + SARS Antigen FIA (Quidel Corporation), BD Veritor SARS CoV-2 Test (BD), and Rapid Covid-19 Antigen test (Danaher Corporation) were launched at the time of pandemic.Roche Diagnostics, in September 2020, did launch SARS-CoV-2 Rapid Antigen test.Abbott, in January 2021, did receive a CE mark for Panbio rapid antigen test, thereby allowing its usage for self-administered sample collection and asymptomatic screening through nose swab.Ortho Clinical Diagnostics, in December 2021, inked an agreement of acquisition with Ortho Clinical Diagnostics for massively expanding the offering of diagnostics.This could be credited to growing geriatric population due to prevalence of infectious diseases all across. Coming to Europe, Germany dominates the market due to players like Qiagen pushing for more than 20% of the market share.North America holds the largest market share with the US being subject to easy accessibility to technologically improvised diagnostic tools and growing demand for diagnostics through increase in incidences of cancer.Key Takeaways from Immunochromatography Kits Market The team of analysts and consultants has employed every bit of research including primary, secondary, and tertiary to execute. Future Market Insights has walked through these facts with future perspectives in its latest market study entitled ‘Immunochromatography Kits Market’. To diagnose parasitic infections like leishmaniasis, parasite protozoa, trypanosomiasis, filariasis, toxoplasmosis, trichomoniasis, and numerous ICTs are being developed. The future is slated to belong to complex immunoassay techniques like ELISA and radioimmunoassay instead of sensitive, precise, and quick approaches. This method also helps in determination of oncogenesis and detecting cancer in every form inclusive of malignant and benign cancer. Advantages like low cost, simple use, and quicker turnaround time have compelled healthcare personnel to use immunochromatography kits in HBV screenings that include medical checks, self-examinations, and epidemiologic surveys. The serological marker most widely used for diagnosis, screening, and evaluation of the antiviral therapy for Hepatitis B is Hepatitis B surface antigen (HBsAg) (HBV’s envelope protein). Also, around 9 Mn people have succumbed to hepatocellular carcinoma, liver failure, cirrhosis of liver, and various other diseases related to Hepatitis B. As per the WHO’s bulletin (2018), over 257 Mn people worldwide are suffering from Hepatitis B. Hepatitis B is another ailment that needs to be controlled. The pandemic prompted companies to be on the toes in this regard. The devices help to test pregnancy as well as stigmatized conditions like HIV as they do empower patients for performing self-tests at homes. These days, home-based lateral flow assay devices do play an important role with respect to managing infectious and cardiovascular diseases. The Covid era made this detection indispensable. The developing economies do have lucrative opportunities to adopt immunochromatography kits, especially with growing awareness about importance of lateral flow assays in these regions.Īlso, the recent outbreaks of diseases like H1N1, Ebola, and Zika have made it inevitable to detect the diseases on an early note. Even though non-communicable ailments are amongst the leading causes of mortality and morbidity, the infectious diseases do stay a basic concern. The fact that infectious diseases continue to spread in spite of noteworthy enhancements in medicine and sanitation can’t be ignored. In its presentation at JPM, Bryant pointed to a total addressable market of $48 billion and an overall estimated installed base of 100,000 instruments.The global Immunochromatography Kits Market stands at US$ 8.1 Bn as of now and is expected to reach US$ 12.1 Billion by the year 2032 at a CAGR of 4.1% between 20. The firm estimates its COVID-19-related revenues will be around $1.5 billion. QuidelOrtho expects to book $2.6 billion in 2022 revenues on top of revenues from its COVID-19 testing products. The instrument pushes “testing where the lab supervisors and the big integrated delivery networks want testing to be done, this allows them the flexibility to do it,” Bryant said. Herpes simplex virus and varicella-zoster virus testing is also part of the planned menu. In the U.S., the panel running on the instrument would provide simultaneous, qualitative detection and differentiation of influenza A, influenza B, respiratory syncytial virus, and SARS-CoV-2 RNA isolated from human nasal or nasopharyngeal swabs. rollout is part of numerous product launches expected in the near term. The company launched Savannah in the EU last April at the European Congress of Clinical Microbiology & Infectious Diseases 2022 (ECCMID 2022). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |